Artelo biosciences announces new data from an initial food effect investigation with art26.12, a novel non-opioid treatment candidate for persistent pain

Safety and pharmacokinetic data support dosing of art26.12 in fed or fasted conditions completion of positive single ascending dose study with a preliminary food effect assessment advances art26.12 toward multiple ascending dose trial solana beach, calif., aug. 25, 2025 (globe newswire) --  artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced encouraging results from its preliminary food effect evaluation with art26.12.
ARTL Ratings Summary
ARTL Quant Ranking